more

Fortress Biotech, Inc. (FBIO)

(Delayed Data from NSDQ)

$2.80 USD

+0.10 (3.70%)

Updated Jan 22, 2020 03:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1 2 3 4 5 S&P	Strong Buy Buy Hold Sell Strong Sell 500	24.66% 17.94% 9.57% 5.30% 2.19% 10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

NA Value | NA Growth | NA Momentum | NA VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Industry Rank:

Top 33% (85 out of 255)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Fortress Biotech, Inc. (FBIO) Quote Overview » News » Fortress Biotech, Inc. (FBIO) Zacks News

Zacks News

Will Fortress Biotech to Surge Higher?

by Zacks Equity Research Published on May 17,2019

As of late, it has definitely been a great time to be an investor Fortress Biotech.

FBIO

biotechs

All You Need to Know About Fortress Biotech (FBIO) Rating Upgrade to Strong Buy

by Zacks Equity Research Published on March 14,2019

Fortress Biotech (FBIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FBIO

earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank

Sarepta (SRPT) Jumps: Stock Rises 8.3%

by Zacks Equity Research Published on February 28,2019

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

SRPT FBIO

Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher

by Zacks Equity Research Published on November 20,2018

Fortress Biotech (FBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ALXN FBIO

medical

Fortress Biotech (FBIO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on November 09,2018

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 37.29% and -1.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

FBIO

earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank

Will Fortress Biotech (FBIO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research Published on November 01,2018

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FBIO

consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate

Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 09,2018

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 25.37% and 30.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

FBIO